Early access to experimental spinal cord injury drug opens for some patients
NCT ID NCT04278235
First seen Feb 03, 2026 · Last updated May 23, 2026 · Updated 14 times
Summary
This program gives people with acute spinal cord injury access to the investigational drug elezanumab before it is officially approved. It is only for those who cannot join other clinical trials and have no other good treatment options. A doctor must decide if the possible benefits outweigh the risks for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE SPINAL CORD INJURY (SCI) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.